Phase 0 2 trials
Phase 0
NCT02659241 Feb 2016 → Dec 2026 expected fallopian tube serous adenocarcinoma , ovarian serous adenocarcinoma , primary peritoneal serous adenocarcinoma M.D. Anderson Cancer Center
Active not recruiting
No outcome recorded
Phase 0
NCT02207010 Jul 2014 → Dec 2015 glioblastoma St. Joseph's Hospital and Medical Center, Phoenix
Completed
No outcome recorded
Phase 1 27 trials
Phase 1
NCT05008913 Oct → Nov 2021 cancer AstraZeneca
Terminated
No outcome recorded
Phase 1
NCT04949425 Sep 2021 → Apr 2022 cancer AstraZeneca
Terminated
No outcome recorded
Phase 1
NCT04959266 Jun 2021 → Jun 2022 cancer AstraZeneca
Terminated
No outcome recorded
Phase 1
NCT04460937 Apr 2021 → Mar 2024 overdue esophageal adenocarcinoma , esophageal squamous cell carcinoma , gastric cardia adenocarcinoma , gastroesophageal junction adenocarcinoma +2 National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT04197713 Jun 2020 → Feb 2023 overdue metastatic malignant neoplasm National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT04462952 Jun 2020 → Sep 2021 neoplasm AstraZeneca
Completed
No outcome recorded
Phase 1
NCT03345784 May 2018 → May 2022 cervical carcinoma , endometrioid adenocarcinoma , uterine corpus cancer , vaginal carcinoma National Cancer Institute (NCI)
Terminated
No outcome recorded
Stop: Enrollment
Phase 1
NCT03333824 Dec 2017 → Jan 2019 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT03313557 Oct 2017 → May 2019 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT03315091 Sep 2017 → Apr 2018 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT03028766 Jun 2017 → Oct 2019 hypopharynx squamous cell carcinoma , larynx cancer , oral cavity squamous cell carcinoma University of Birmingham
Completed
No outcome recorded
Phase 1
NCT02791919 May 2017 → May 2019 aneurysm, intracranial berry, 2 , childhood acute myeloid leukemia National Cancer Institute (NCI)
Withdrawn
No outcome recorded
Phase 1
NCT02546661 Dec 2016 → Mar 2020 overdue infiltrating bladder urothelial carcinoma AstraZeneca
Active not recruiting
No outcome recorded
Phase 1
NCT02906059 Sep 2016 → Mar 2020 colorectal cancer NYU Langone Health
Completed
No outcome recorded
Phase 1
NCT02617277 Dec 2015 → Apr 2019 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT02610075 Dec 2015 → Apr 2018 metastatic neoplasm , ovarian cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT02585973 Oct 2015 → Jun 2019 head and neck squamous cell carcinoma UNC Lineberger Comprehensive Cancer Center
Completed
No outcome recorded
Phase 1
NCT02381548 Aug 2015 → May 2018 blast phase chronic myelogenous leukemia, BCR-ABL1 positive , myelodysplastic syndrome , therapy related acute myeloid leukemia and myelodysplastic syndrome National Cancer Institute (NCI)
Terminated
No outcome recorded
Phase 1
NCT02511795 Aug 2015 → Apr 2019 refractory malignant neoplasm , small cell lung carcinoma AstraZeneca
Completed
No outcome recorded
Phase 1
NCT02508246 Jul 2015 → Apr 2018 head and neck squamous cell carcinoma University of Washington
Completed
No outcome recorded
Phase 1
NCT02482311 Jul 2015 → Jan 2018 —
AstraZeneca
Completed
No outcome recorded
Phase 1
NCT02341456 Jan 2015 → Dec 2016 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT01849146 Oct 2013 → Jul 2021 glioblastoma National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1
NCT01922076 Sep 2013 → Dec 2020 anaplastic astrocytoma , anaplastic oligoastrocytoma , diffuse midline glioma, H3 K27M-mutant , gliosarcoma National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1
NCT01748825 Dec 2012 → May 2020 cancer National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1
NCT01047007 Jan 2010 → Jun 2011 cancer Merck Sharp & Dohme LLC
Terminated
No outcome recorded
Stop: Business
Phase 1
NCT00648648 Feb 2008 → Jan 2014 cancer Merck Sharp & Dohme LLC
Completed
No outcome recorded
Show 17 more trials Phase 1/2 5 trials
Phase 1/2
NCT02813135 Aug 2016 → Feb 2031 expected childhood malignant neoplasm Gustave Roussy, Cancer Campus, Grand Paris
Recruiting
No outcome recorded
Phase 1/2
NCT02194829 Aug 2014 → Jun 2021 pancreatic adenocarcinoma National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1/2
NCT02095132 Mar 2014 → Dec 2020 childhood supratentorial embryonal tumor with multilayered rosettes, C19MC-altered , ganglioneuroblastoma , medulloblastoma , neuroblastoma +3 National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1/2
NCT02037230 Jan 2014 → Aug 2018 pancreatic adenocarcinoma University of Michigan Rogel Cancer Center
Completed
No outcome recorded
Phase 1/2
NCT01076400 May 2010 → Jun 2011 cervical cancer Merck Sharp & Dohme LLC
Terminated
No outcome recorded
Stop: Enrollment
Phase 2 26 trials · 1 met primary · 2 missed
Phase 2
NCT05212025 Jun 2022 → Jun 2023 malignant pancreatic neoplasm James Cleary, MD, PhD
Withdrawn
No outcome recorded
Phase 2
NCT04590248 Nov 2020 → May 2022 endometrial serous adenocarcinoma AstraZeneca
Completed
No outcome recorded
Phase 2
NCT03718143 May → Sep 2019 acute myeloid leukemia , myelodysplastic syndrome , myelofibrosis NYU Langone Health
Terminated
No outcome recorded
Phase 2
NCT03284385 Jan 2019 → Mar 2026 overdue clear cell renal carcinoma , metastatic malignant neoplasm National Cancer Institute (NCI)
Active not recruiting
Missed primary
Phase 2
NCT03253679 Jan 2019 → Oct 2022 high grade malignant neoplasm National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 2
NCT03579316 Dec 2018 → Dec 2026 expected fallopian tube carcinoma , ovarian carcinoma , primary peritoneal carcinoma M.D. Anderson Cancer Center
Active not recruiting
No outcome recorded
Phase 2
NCT03668340 Oct 2018 → Sep 2026 overdue uterine cancer Dana-Farber Cancer Institute
Active not recruiting
No outcome recorded
Phase 2
NCT03385655 Aug 2018 → Oct 2024 overdue prostate cancer Canadian Cancer Trials Group
Active not recruiting
No outcome recorded
Phase 2
NCT02666950 May 2017 → Sep 2018 acute myeloid leukemia , chronic myelomonocytic leukemia , myelodysplastic syndrome associated with isolated del(5q) Mayo Clinic
Completed
No outcome recorded
Phase 2
NCT04439227 Mar 2017 → May 2020 overdue plasma cell myeloma , refractory malignant neoplasm National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2
NCT03012477 Jan 2017 → May 2019 triple-negative breast carcinoma Dana-Farber Cancer Institute
Completed
No outcome recorded
Phase 2
NCT02937818 Nov 2016 → Jun 2020 —
AstraZeneca
Completed
No outcome recorded
Phase 2
NCT02688907 Jun 2016 → Dec 2017 small cell lung carcinoma Samsung Medical Center
Terminated
No outcome recorded
Phase 2
NCT02593019 Dec 2015 → Oct 2018 small cell lung carcinoma Samsung Medical Center
Completed
No outcome recorded
Phase 2
NCT02576444 Nov 2015 → Nov 2019 cancer Joseph Paul Eder
Terminated
No outcome recorded
Phase 2
NCT02513563 Oct 2015 → Nov 2022 lung cancer H. Lee Moffitt Cancer Center and Research Institute
Completed
No outcome recorded
Phase 2
NCT02465060 Aug 2015 → Dec 2027 expected breast carcinoma , carcinoma of esophagus , cervical carcinoma , colon carcinoma +17 National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2
NCT02272790 Jan 2015 → Dec 2018 neoplastic disease or syndrome AstraZeneca
Completed
No outcome recorded
Phase 2
NCT02448329 Jan 2015 → Dec 2019 gastric adenocarcinoma Samsung Medical Center
Completed
No outcome recorded
Phase 2
NCT02101775 Jul 2014 → Feb 2022 overdue fallopian tube carcinoma , ovarian Brenner tumor , ovarian carcinosarcoma , ovarian clear cell cystadenocarcinoma +7 National Cancer Institute (NCI)
Active not recruiting
Met primary
Phase 2
NCT02196168 Mar 2014 → Apr 2016 hypopharynx squamous cell carcinoma , larynx verrucous carcinoma , metastatic squamous cell carcinoma , nasal cavity and paranasal sinus squamous cell carcinoma +3 National Cancer Institute (NCI)
Terminated
No outcome recorded
Stop: Enrollment
Phase 2
NCT02087241 Mar 2014 → Jun 2015 —
AstraZeneca
Terminated
No outcome recorded
Phase 2
NCT02087176 Mar 2014 → May 2015 non-small cell lung carcinoma AstraZeneca
Terminated
No outcome recorded
Phase 2
NCT01827384 Jan 2014 → Jun 2021 cancer National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 2
NCT01357161 Jul 2011 → Aug 2016 ovarian cancer Merck Sharp & Dohme LLC
Completed
Missed primary
Phase 2
NCT01164995 Jul 2010 → Apr 2023 malignant epithelial tumor of ovary The Netherlands Cancer Institute
Completed
No outcome recorded
Show 16 more trials Comparator or background therapy 1 trial
Phase 2
NCT03330847 Comparator Mar 2018 → Nov 2020 overdue triple-negative breast carcinoma AstraZeneca
Active not recruiting
No outcome recorded